|
1）Cruz DN, Goh CY, Haase-Fielitz A, et al. Early biomarkers of renal injury. Congest Heart Fail. 2010; 16 : 25-31
|
|
|
|
|
2）The Kidney Disease : Improving Global Outcome : Clinical practice guideline on acute kidney injury 2012. Kidney Int Supple. 2012; 2: 1-138
|
|
|
|
|
|
3）Himmelfarb J, Ikizler TA. Acute kidney injury: changing lexicography, definitions, and epidemiology. Kidney Int. 2007; 71: 971-6
|
|
|
|
|
4）Go AS, Chertow GM, Fan D, et al. Chronic kidney disease and the risks of death, cardiovascular events, and hospitalization. N Engl J Med. 2004; 351: 1296-305
|
|
|
|
|
|
5）Ninomiya T, Kiyohara Y, Kubo M, et al. Chronic kidney disease and cardiovascular disease in a general Japanese population. Kidney Int. 2005; 68: 228-36
|
|
|
|
|
|
6）Negishi K, Noiri E, Doi K, et al. Monitoring of urinary L-type fatty acid-binding protein predicts histological severity of acute kidney injury. Am J Pathol. 2009; 174: 1154-9
|
|
|
|
|
|
7）Portilla D, Dent C, Sugaya T, et al. Liver fatty acid-binding protein as a biomarker of acute kidney injury after cardiac surgery. Kidney Int. 2008; 73: 465-72
|
|
|
|
|
|
8）Nakamura T, Sugaya T, Node K, et al. Urinary excretion of liver-type fatty acidbinding protein in contrast medium-induced nephropathy. Am J Kidney Dis. 2006; 47:439-44
|
|
|
|
|
|
9）Kamijyo A, Sugaya T, Hikawa A, et al. Clinical evaluation of urinary execretion of liver-type fatty acid-binding protein as a marker for the monitoring of chronic kidney disease: A multicenter trial. J Lab Clin Med. 2005; 145: 125-33
|
|
|
|
|
|
10）Mishra J, Ma Q, Prada A, et al. Identification of neutrophil gelatinase-associated lipocalin as a novel early urinary biomarker for ischemic renal injury. J Am Soc Nephrol. 2003; 14: 2534-43
|
|
|
|
|
|
11）日本腎臓学会, 編. CKD診療ガイド2012. 東京: 東京医学社; 2012
|
|
|
|
|
|
12）Nakano C, Hamano T, Fujii N, et al. Combined use of vitamin D status and FGF23 for risk stratification of renal outcome. Clin J Am Soc Nephrol. 2012; 7: 810-9
|
|
|
|
|
|
13）Sarah S, Brigit R, Daniel R, et al. FGF-23 and future cardiovascular events in patients with chronic kidney disease before initiation of dialysis terrment.Nephrol Dial Transplant. 2010; 25: 3983-9
|
|
|
|
|
|
14）Titan SM, Zatz R, Graciolli FG, et al. FGF-23 as a predictor of outcome in diabetic nephropathy. Clin J Am Soc Nephrol. 2011; 6: 241-7
|
|
|
|
|
|
15）Hu MC, Shi M, Zhang J, et al. Klotho deficiency causes vascular calcification in chronic kidney disease. J Am Soc Neprol. 2011; 22: 124-36
|
|
|
|
|
|
16）Shimamura Y, Hamada K, Inoue K, et al. Serum levels of soluble secreted a-Klotho are decreased in the early stages of chronic kidney disease, making it a probable novel biomarker for early diagnosis. Clin Exp Nephrol. 2012; 5: 722-9
|
|
|
|
|
|
17）Martin B, Marc V, Piet W, et al. Cross talk between the renin-angiotensin-aldosterone system and vitamin D-FGF-23-klotho in chronic kidney disease. J Am Soc Nephrol. 2011; 22: 1603-9
|
|
|
|
|
|
18）Sun CY, Chang SC, Wu MS. Suppression of Klotho expression by protein-bound uremic toxins is associated with increased DNA methyltransferase expression and DNA hypermethylation. Kidney Int. 2012; 81: 640-50
|
|
|
|
|
|
19）Watanabe N, Bokuda K, Fujiwara T, et al. Soluble(pro)renin receptor and blood pressure during pregnacy: a prospective cohort study. Hypertension. 2008; 60: 1250-6
|
|
|
|
|
|
20）Hamada K, Taniguchi Y, Shimamura Y, et al. Serum level of soluble(pro)renin receptor is modulated in chronic kidney disease. Clin Exp Nephrol. 2013; 17: 848-56
|
|
|
|